Cabozantinib in Men With Castration-Resistant Prostate Cancer

NCT01703065 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Closed 2017 for low accrual. Last data for primary outcome on 02Feb2015.

Conditions

Adenocarcinoma of the Prostate
Castration-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage III Prostate Cancer
Stage IV Prostate Cancer

Interventions

DRUG: Cabozantinib

Sponsor

University of Washington

Collaborators

[object Object]
[object Object]